Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rajni A. Jibodh"'
Autor:
Erwin Krikken, Vitaliy Khlebnikov, Moritz Zaiss, Rajni A. Jibodh, Paul J. van Diest, Peter R. Luijten, Dennis W. J. Klomp, Hanneke W. M. van Laarhoven, Jannie P. Wijnen
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-9 (2018)
Abstract Background The purpose of this work was to investigate noninvasive early detection of treatment response of breast cancer patients to neoadjuvant chemotherapy (NAC) using chemical exchange saturation transfer (CEST) measurements sensitive to
Externí odkaz:
https://doaj.org/article/12d4411f4453484ca3d2c4080fd4de21
Autor:
Maarten F. Bijlsma, Sybren L. Meijer, Kausilia K. Krishnadath, Gerrit K. J. Hooijer, S S Gisbertz, Aafke Creemers, Martijn G.H. van Oijen, Mark I. van Berge Henegouwen, Hanneke W. M. van Laarhoven, Maurits L. van Montfoort, Eva A. Ebbing, Lisanne Stap, Rajni A Jibodh-Mulder, Maarten C.C.M. Hulshof
Publikováno v:
Oncotarget, 9(42), 26787-26799. Impact Journals
Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarci
Autor:
Moritz Zaiss, Rajni A. Jibodh, Dennis W.J. Klomp, Vitaliy Khlebnikov, Jannie P. Wijnen, Erwin Krikken, Paul J. van Diest, Peter R. Luijten, Hanneke W. M. van Laarhoven
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research
Breast Cancer Research, Vol 20, Iss 1, Pp 1-9 (2018)
Breast Cancer Research, 20(1). BioMed Central
Breast cancer research, 20(1):51. BioMed Central
Breast Cancer Research
Breast Cancer Research, Vol 20, Iss 1, Pp 1-9 (2018)
Breast Cancer Research, 20(1). BioMed Central
Breast cancer research, 20(1):51. BioMed Central
Background The purpose of this work was to investigate noninvasive early detection of treatment response of breast cancer patients to neoadjuvant chemotherapy (NAC) using chemical exchange saturation transfer (CEST) measurements sensitive to amide pr
Publikováno v:
European Journal of Pharmacology. 717:40-46
Oral administration of anticancer drugs is most often preferred over intravenous administration, as it is convenient for patients, prevents hospitalisation and reduces costs of the therapy. However, the oral route is often hampered by low oral bioava